Alkermes PLC (NAS:ALKS)
$ 24.34 -0.04 (-0.16%) Market Cap: 4.12 Bil Enterprise Value: 3.75 Bil PE Ratio: 9.62 PB Ratio: 3.28 GF Score: 66/100

Alkermes Plc at Stifel Healthcare Conference Transcript

Nov 19, 2019 / 06:15PM GMT
Release Date Price: $18.55 (-1.04%)
Nathaniel Tower
Stifel, Nicolaus & Company, Incorporated, Research Division - Associate

All right. I think we're good to go. So I'm Nate Tower. I'm a member of the Stifel Research team on Paul Matteis' Biotech team. I'm happy to be joined by Blair Jackson, who's SVP of Corporate Planning for Alkermes. And I think we'll just have a 0.5 hour chat about the business. And I was hoping maybe we could just start it off. For those who are newer to the story, maybe you can give a brief overview of where the company has been, where it is today and where it's going?

Blair C. Jackson
Alkermes plc - SVP of Corporate Planning

Great. Well, thanks for having me today. I'm really happy to be talking about Alkermes. It's been an exciting year. 2019, there's been just a lot of changes fundamentally in the company.

We've really built a strong commercial organization on the back of a really interesting portfolio of CNS products. So we have a product called VIVITROL for the treatment of addiction, specifically opioid dependence and alcohol dependence. And it's a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot